Abstract: The present application generally relates to the field of biotechnology and, in particular, to an anti-PD-1 single-domain antibody. The present application provides an anti-PD-1 single-domain antibody, which includes complementary determining regions including CDR1 having an amino acid sequence as set forth in one of SEQ ID Nos. 5 to 6, CDR2 having an amino acid sequence as set forth in one of SEQ ID Nos. 9 to 12, and CDR3 having an amino acid sequence as set forth in one of SEQ ID Nos. 17 to 21. The anti-PD-1 single-domain antibody provided by the present disclosure has specific binding ability for PD-1 and can be used to further construct fusion proteins, etc., which can also increase IFN-? and/or IL-2 expression in T lymphocytes and can effectively inhibit tumor growth, and therefore has good prospects for industrialization.

Abstract: Provided herein are PD-1 agonist antibodies which bind PD-1. The PD-1 agonist antibodies of the disclosure are useful for the treatment of autoimmune and inflammatory diseases through the promotion of PD-1 signaling. Also provided herein are methods of use for the PD-1 agonist antibodies.

Abstract: The present invention provides a B7-H3 nanobody, the preparation method and use thereof. The B7-H3 nanobody comprises framework regions 1-4 (FR 1-4) and complementarity determining regions 1-3 (CDR 1-3), can specifically bind to B7-H3, and can be used for detecting B7-H3 molecules, and be used for the treatment of various malignant tumors with abnormal expression of B7-H3 molecule.

Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.

Abstract: The present invention generally relates to antibody combinations and uses thereof.

Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: An antibody or fragment thereof, compositions, and methods of use related to depletion, inhibition, or depletion and inhibition of plasmacytoid dendritic cells (pDC), are disclosed.

Abstract: This disclosure relates generally to a method of inhibiting epithelial cell proliferation including the treatment of conditions associated with aberrant epithelial cell proliferation in mammals, including animals and humans. The present disclosure is particularly relevant for the treatment of cancer.

Abstract: [Problem] Provided is a multispecific antibody for preventing or treating amyotrophic diseases such as inclusion body myositis by binding to ActRIIA, ActRIIB, and Fn14, and inhibiting an amyotrophic action which occurs via ActRIIA, ActRIIB, and Fn14. [Means for Solution] The present inventors have conducted studies on a multispecific antibody, and provided a multispecific antibody including a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 and a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4.

Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Abstract: The present technology provides T cell recruiting polypeptides that specifically bind to the constant domain of a human and of a non-human primate TCR. The present technology also provides nucleic acids, vectors, and compositions. The polypeptides can be used in methods for treatment of cancer.

Abstract: The present disclosure relates to a dual inhibiting antibody that targets human interleukin-4 and interleukin-13, a manufacturing method therefor and use thereof.

Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Abstract: The present invention provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles. The present invention also provides an antibody that binds to an NTCP, capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles, the antibody having a reduced effect on bile acid transport by NTCP.

Abstract: Provided is a CD5-targeting fully human antibody or an antigen-binding fragment thereof, which specifically binds to CD5 with a high affinity, has a lower immunogenicity compared to heterologous antibodies, and has a good application potential in the development of antibody drugs, cell therapy drugs, detection reagents and the like.

Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer and fibrosis.

Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

Abstract: A composition that binds to an anti-CD47 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD47 and/or a fragment thereof that interferes with binding activity of the anti-CD47 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD47 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD47 antibodies.

Abstract: The present invention provides an antibody binding a human tumor-associated calcium signal sensor 2 (Trop-2) protein or fragments thereof, and use of the antibody or fragments thereof in preventing or treating diseases. The antibody or fragments thereof of the present invention can effectively bind to the human Trop-2 protein, and have internalization activity, and the internalization activity is enhanced after ADC drug labeling, and the in vivo efficacy and safety of a mouse model are not lower than those of a control antibody.

Abstract: Provided herein are antibodies that selectively bind to TROP2 and CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.

Abstract: Entirely carbohydrate immunogens, monoclonal antibodies generated from immune responses to entirely carbohydrate immunogens, vaccine compositions, pharmaceutical compositions, and methods of making and using the same, are described.

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: Provided are methods and compositions comprising antibodies capable of specific binding to human CEACAM1 molecules, for treating and diagnosing cancer as well as assessing CEACAM1 expression in tumor infiltrating immune cells (TILs) in a biological sample obtained from a [cancer] subject.

Abstract: The present disclosure provides anti-Tn antibodies (e.g., BaGs6 and/or Remab6) having superior specificity for Tn antigen on cancer cells. Also provided herein, are nucleic acids, vectors, or vector sets that encode the anti-Tn antibody.

Abstract: In one aspect, the present disclosure relates to a method for treating or ameliorating the effects of a HER2 positive breast cancer in a subject by administration of a combination of tucatinib, capecitabine, and trastuzumab. In some embodiments, the methods provided herein are useful for treating or ameliorating the effects of a HER2 positive breast cancer-associated brain metastasis in a subject by administration of a combination of tucatinib, capecitabine, and trastuzumab.

Abstract: HER3 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the HER3 antigen-binding molecules.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: Provided herein are novel bispecific antibodies for the treatment of chronic pain. The bispecific antibodies comprise two or more antigen binding components, wherein at least one antigen binding component is capable of binding to human ADAMTS5, and wherein at least one antigen binding component is capable of binding to nerve growth factor (NGF).

Abstract: A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric. When administered in a therapeutic quantity, symptoms of necrotizing enterocolitis in the subject are inhibited or precluded.

Abstract: Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.

Abstract: The invention relates to trimeric polypeptide complex comprising three monomer polypeptides wherein each monomer polypeptide comprises an anti-4-1BB specific agonistic single-chain antibody fragment (scFv), a homotrimerization domain and a polypeptide region which is capable of specifically binding to a tumor associated antigen. The invention also relates to said trimeric polypeptide complexes for use in the treatment of cancer.

Abstract: The present invention provides a high-purity glucose-based compound ultra-highly substituted with a biopolymer, in which a surface of a glucose-based compound as a natural material is ultra-highly modified with a biopolymer to improve compatibility and dispersibility with biodegradable polymers, thereby significantly improving the mechanical properties of the biodegradable polymer composite.

Abstract: Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex. In certain aspects, the dextran-chelator complex is substantially free of intra- or intermolecular crosslinking. In certain aspects, the functionalized dextran is an amine dextran, an alkynyl dextran, or a thiol dextran. In exemplary implementations, the functionalized dextran is an amine dextran. In further embodiments, one and only one carboxylic acid group on the chelating agent is derivatized as a N-hydroxysuccinimide (NHS) ester.

Abstract: In one aspect, the disclosure relates to self-healing systems including at least a structural polymer, a plurality of optical fibers or polymer waveguides embedded in the structural polymer, and a plurality of micro-channels through the structural polymer, wherein the micro-channels are configured to deliver a curing composition to at least one site of damage in the system. In another aspect, the curing composition can include a photo-polymerizable liquid monomer, and, optionally, a sensitizer, a photo-initiator, and/or a toughening agent, articles comprising the same, and methods of in situ self-healing of damage including Mode-I fractures using visible irradiation from the optical fibers or polymer waveguides to photo-polymerize the liquid monomer.

Abstract: Liquid radiation curable compositions are disclosed which are suitable for hybrid (i.e. cationic and free-radical) polymerization when processed via additive fabrication equipment utilizing sources of actinic radiation with peak spectral intensities in the UV/vis region. According to one aspect, the compositions possess a first photoinitiator that is an iodonium salt of a non-fluorinated borate anion. According to another aspect, the composition is substantially devoid of a Norrish Type I and/or Type II photoinitiator. Also disclosed are methods of creating three-dimensional parts via additive fabrication processes utilizing sources of actinic radiation with peak spectral intensities in the UV/vis region employing liquid radiation curable compositions suitable for hybrid polymerization, and the parts cured therefrom.

Abstract: The present disclosure relates to supported catalyst systems for olefin polymerization, catalyst system precursors, methods of producing the precursors and catalyst systems and polyolefins formed from the catalyst systems.

Abstract: The present invention relates to a process for continuously producing an ultra-high molecular weight polyethylene by the ethylene slurry polymerization, wherein raw materials containing ethylene and optionally at least one comonomer are subjected to a continuous slurry polymerization in a hydrogen free atmosphere in the ethylene slurry polymerization condition by using 2-6 ethylene slurry polymerization reaction tanks connected in series, and the deviations of the polymerization temperatures, the polymerization pressures, and the gas phase compositions between the tanks each other are controlled to certain ranges. The ultra-high molecular weight polyethylene having the viscosity-average molecular weight of 150-800×104 g/mol can be continuously produced. This process has flexible polymerization manner, large room for adjusting and controlling, and stable polymer performance.

Abstract: A process for polymerization of vinyl chloride may include contacting vinyl chloride, demineralized water, at least one stabilizer agent, at least one dispersing agent, an initiator and optionally one or more comonomers; continuously feeding the vinyl chloride, demineralized water, at least one stabilizer agent, at least one dispersing agent, an initiator and optionally one or more comonomers into a tubular reactor having a length of at least 20 times an internal diameter of the tubular reactor; and continuously polymerizing the vinyl chloride, and optionally the one or more comonomers.

Abstract: The present application relates to a method of performing living cationic polymerization of monomers by supermolecular anion-binding catalysis. It uses various simple Bronsted acids or adducts thereof with a monomer as the cationic initiator, and various hydrogen bond donors as the catalyst for binding and dissociating counter anions dynamically, to living and controlled polymerize one or more cationically polymerizable monomers to form a homopolymer or a copolymer.

Abstract: The present disclosure relates to a photo-curable composition, a cured product thereof, and an optical member and a display device comprising same. The photo-curable composition has excellent low refractive index, light transmittance, and low haze characteristics by comprising a first olefinic monomer containing fluorine, a second olefinic monomer having an absolute viscosity of 7 cP or less at 25° C., a photo-polymerization initiator, and an amine compound.

Abstract: Processes of polymerizing olefin monomers.

Abstract: The present invention provides a novel copolymer available for a drug delivery technique. More particularly, a novel copolymer for a drug delivery carrier targeting a tumor is provided. The present invention relates to a copolymer comprising structural units represented by the following formulas (A), (B), and (C): wherein R1, R2, and R3 are the same or different and represent a hydrogen atom or a C1-3 alkyl group, R4 represents a C1-3 alkyl group, R5 represents a hydrogen atom, a C1-18 alkyl group, a 3- to 8-membered cycloalkyl group optionally having a substituent, an adamantyl group, a C6-18 aryl group optionally having a substituent, or a 5- to 10-membered heteroaryl group optionally having a substituent, X1, X2, and X3 are the same or different and represent an oxygen atom, a sulfur atom, or N—R7, R6 represents a hydrogen atom, a leaving group, or a linker, R7 represents a hydrogen atom or a C1-3 alkyl group, m represents an integer of 1 to 100, and n represents an integer of 0 to 3.

Abstract: A disclosed polymer thin film includes a cationic polymer having a hydrolyzable side chain. The polymer thin film has a surface potential of 1 mV to 50 mV. A hydrolysis efficiency of the cationic polymer is 30% or more after reaction at 50° C. for one hour. The cationic polymer is dissolved to three-dimensionally capture nucleic acids, and releases the nucleic acids through hydrolysis. Thus, nucleic acid capturing-releasing efficiency can be improved.

Abstract: The invention provides a method for producing a polymer used as a base film for cell culture which comprises (i) preparing a mixture containing (a) a monomer of formula (I): wherein Ua1 and Ua2 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, Ra1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, and Ra2 represents a linear or branched alkylene group having 1 to 5 carbon atoms, (b) a radical polymerization initiator, and (c) an organic solvent, and (ii) preparing a polymer by raising a temperature of the mixture under stirring to polymerize the monomer. The invention also provides methods of producing a base film for cell culture and a cell culture container.

Abstract: Provided is a polymer including a constituent unit (1) based on a monomer represented by Formula (1), in which a content of a constituent unit based on a monomer having a polycyclic structure is 35 mol % or less. In Formula (1), R1 represents a hydrogen atom or a methyl group, A1 represents a linking group including an ester bond, or a single bond, where A1 has no tertiary carbon atom, and Z1 represents an atomic group forming a sulfur-containing cyclic hydrocarbon group having 3 to 6 carbon atoms, which includes a carbon atom bonded to A1, and —SO2—.

Abstract: A system for continuously treating recycled polystyrene material includes a hopper/densifier configured to feed recycled polystyrene material into the system. An extruder can turn the recycled polystyrene material into a molten material. In some embodiments, the extruder uses thermal fluids, electric heaters, and/or a separate heater. Solvents, such as toluene, xylenes, cymenes, and/or terpinenes can aid in generating the molten material. The molten material can be depolymerized in a reactor and a catalyst can be used to aid the depolymerizing. In certain embodiments, the catalyst is contained in a permeable container. In some embodiments, copolymers/monomers are grafted onto the depolymerized material. The depolymerized molten material can be cooled via a heat exchanger. The product can be isolated by extraction, distillation, and/or separation. In some embodiments, the product is treated through filtration and absorption media. In some embodiments, multiple reactors are used.